COMMUNIQUÉS West-GlobeNewswire

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
10/04/2024
Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and effective treatment for Cyclin E-overexpressing cancers IND for APR-1051 has been cleared; [...]
Ongoing Point of Care Ultrasound Certification Academy Study Aims to Identify Top 25 POCUS Practice Domains
10/04/2024
Study aims to help establish global curriculum and credentialing guidelines for clinicians and educators ROCKVILLE, Md., April 10, 2024 (GLOBE NEWSWIRE) -- Inteleos, a non-profit global healthcare certification [...]
University Cancer & Blood Center and University Health Alliance open High-Risk GI Clinic to address community needs
10/04/2024
State-of-the-art program features acclaimed physicians and experts in oncology and gastroenterology ATHENS, Ga., April 10, 2024 (GLOBE NEWSWIRE) -- University Cancer & Blood Center (UCBC), a leading oncology and [...]
EUROBIO SCIENTIFIC: RESULTAT ANNUEL 2023
10/04/2024
RESULTAT ANNUEL 2023 Croissance du cœur d’activité et déploiement stratégique Chiffre d’affaires Cœur d’activité 1 en croissance de 39% à 130 M€ les produits propriétaires atteignent 30% du CA la part du CA hors France [...]
EUROBIO SCIENTIFIC: 2023 ANNUAL RESULTS
10/04/2024
2023 ANNUAL RESULTS Growth in Core Business and strategic deployment Core business 1 revenues up 39% to €130m proprietary products account for 30% of revenues 38% of revenues generated outside France Resilient results [...]
FirstClass Healthcare Earns Perfect Score on NCCHC (National Commission on Correctional Health Care) Accreditation in the Gwinnett County Jail
10/04/2024
GWINNETT COUNTY, Ga., April 10, 2024 (GLOBE NEWSWIRE) -- FirstClass Healthcare , an Atlanta-based correctional and institutional healthcare organization, earned a perfect score from the National Commission on [...]
Major shareholder announcement – BlackRock, Inc.
10/04/2024
ANNOUNCEMENT NO. 260 Major shareholder announcement Major shareholder announcement – BlackRock, Inc. Pursuant to Section 30 of the Capital Markets Act, it is hereby announced that BlackRock, Inc. has informed ChemoMetec [...]
Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
10/04/2024
Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 10 avril 2024 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe et [...]
Acryno To Blends AI and Luxury Concierge Services to Reimagine Healthcare
10/04/2024
The novel platform seeks to match patients with skilled medical experts to democratize access to quality providers and cut down on wait times for care NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- In an era of rising [...]
NeuroOne® CEO Dave Rosa Featured on Bloomberg Technology
10/04/2024
EDEN PRAIRIE, Minn., April 10, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and [...]
Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study
10/04/2024
The study results revealed improvements in symptoms and quality of life in patients with musculoskeletal pain and inflammation TORONTO, April 10, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company [...]
Joint Statement Applauding Final Rule for Web Accessibility Under Title II of the ADA
10/04/2024
WASHINGTON, April 10, 2024 (GLOBE NEWSWIRE) -- The American Council of the Blind (ACB), the American Foundation for the Blind (AFB), the National Disability Rights Network (NDRN), and the National Federation of the [...]
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
10/04/2024
Lack of early symptom improvement is not predictive of final responder status MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, [...]
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
10/04/2024
Findings underscore the liver safety of AD04 as compared to placebo in the prior Phase 3 clinical trial GLEN ALLEN, Va., April 10, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “ [...]
BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference
10/04/2024
MISSISSAUGA, Ontario, April 10, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2024 Bloom Burton & Co. Healthcare Investor [...]
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
10/04/2024
VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 2024 Bloom [...]
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
10/04/2024
FREMONT, CA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS ( [...]
Nexalin Technology CEO Provides Letter to Shareholders
10/04/2024
Reports on growing clinical data supporting its neurostimulation technology and progress advancing its new Gen-3 HALO™ Clarity Virtual Clinic model HOUSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. ( [...]
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
10/04/2024
OCALA, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda (pembrolizumab) in [...]

Pages